PDCD1 and neoplasm: Researches have shown that PD-L1 expression is upregulated in tumor cells, which activates PD-1/PD-L1 downstream pathways by specifically binding to PD-1 on the surface of cytotoxic T lymphocytes (CTLs) to deliver negative regulatory signals.